TCTR20211023002已完成4 期
Safety, tolerability, and antibody response after intradermal vaccination of COVID-19 vaccine; PFE-BNT in adults who have completed two-doses of Verocell (inactivated vaccine)
ampang Hospital0 个研究点目标入组 42 人开始时间: 2021年10月23日最近更新:
适应症
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 发起方
- 入组人数
- 42
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 Years 至 N/A (No limit)（—）
- 性别
- All
入选标准
- •participants were adults aged more than 18 years who completed 2 doses of a three-week schedule of Verocell, and have not had SARS-CoV-2 infection.
排除标准
- •Participants were excluded from the study if they: had history of severe adverse or allergic reactions to previous vaccinations, were pregnancy or planned pregnancy within 4 weeks after vaccination, used of systemic or topical corticosteroids, had bleeding diathesis , received other Covid-19 vaccine, and had SARS-CoV-2 infection before collecting post ID injection blood sample.
研究者
相似试验
招募中
4 期
Immunologic response to hepatitis B immunization in children post liver transplantatioSafety and efficacy of hepatitis B vaccine, standard compare to double dose in short and long term follow-up.infection, bleeding, painTCTR20180723002Chulalonkorn University72
Unknown
3 期
BNT162b2 in Thai childreImmunization to prevent COVID-19 infection.COVID-19, vaccination, BNT162b2, children, liver transplant, immunogenicity, safetyTCTR20220708003Chulalongkorn University33
招募中
3 期
Safety, humoral and cellular immunogenicity after coronavirus disease-19 (COVID-19) vaccination (BNT162b2) in 12 to 18 year-old children after liver transplantatioImmunization to prevent COVID-19 infectionCOVID-19, vaccination, BNT162b2, adolescent, liver transplant, immunogenicity, safetyTCTR20210830002Chulalongkorn university44
招募中
不适用
Assessment of the safety, tolerance, and immunogenicity of EG-HPV (human papillomavirus vaccine) in healthy male adult volunteers:KCT0000604Eyegene24
进行中（未招募）
1 期
India Registration Study for Quadrivalent HPV VaccineEUCTR2017-000111-16-Outside-EU/EEAMerck & Co., Inc.110